Tag: a clinical-stage biotechnology company commercializing a novel vaccination platform
Vaxxas raises $34 million to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.
Featured Article
Beyond insights: CRM’s transformative role in sustainable manufacturing
Manufacturing companies worldwide are increasingly gearing up for a significant transformation with environmental sustainability at the centre. This comes amid stronger environmental regulations, a shift in consumer behaviour, and the industrial sector delves deeper into Industry 4.0.
